Get started
Author

Diogo Magalhães

Observed names: D. B. Magalhães, Diogo Magalhaes, Magalhaes, Diogo, Magalhães, Diogo
Institution: Bial (Portugal)
ORCID: 0000-0002-0800-9136
Observed ORCID: 0000-0002-0800-9136
OpenAlex ID: A5045428922
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
2020 · the OPTIPARK investigators, Heinz Reichmann, et al. · Translational Neurodegeneration · 73
PDF
Role of epithelial ion transports in inflammatory bowel disease
2016 · Diogo Magalhães, José Miguel Cabral, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 56
PDF
Melissa officinalis L. ethanolic extract inhibits the growth of a lung cancer cell line by interfering with the cell cycle and inducing apoptosis
2018 · D. B. Magalhães, I. Castro, et al. · Food & Function · 45
The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers
2021 · Eduardo Tolosa, Georg Ebersbach, et al. · Journal of Parkinson s Disease · 27
PDF
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
2021 · Fernando Magro, Diogo Magalhães, et al. · Clinical Gastroenterology and Hepatology · 24
PDF
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
2021 · José-Francisco Rocha, Georg Ebersbach, et al. · Frontiers in Neurology · 20
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
2023 · Diogo Magalhaes, Laurent Peyrin-Biroulet, et al. · Therapeutic Advances in Gastroenterology · 15
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
2022 · K. Ray Chaudhuri, Per Odin, et al. · BMC Neurology · 15
PDF
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
2022 · José-Francisco Rocha, Georg Ebersbach, et al. · Frontiers in Neurology · 10
The effect of PRR ligands on the membrane potential of intestinal epithelial cells
2017 · Diogo Magalhães, Patrício Soares-da-Silva, et al. · Pharmacological Reports · 9
Amine neurotransmitters, inflammation and epithelial sodium transport
2015 · Patrício Soares‐da‐Silva, José Miguel Cabral, et al. · Experimental Physiology · 8
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
2020 · the OPTIPARK investigators, Heinz Reichmann, et al. · Translational Neurodegeneration · 4
PDF
Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study
2026 · Kallol Ray Chaudhuri, Joaquim J. Ferreira, et al. · Movement Disorders · 1
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: Findings from the real-world OPTIPARK study
2021 · Nicola Pavese, Andrew Lees, et al. · Journal of the Neurological Sciences · 1
PDF
Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson's disease patients with motor fluctuations and reporting troublesome dyskinesia
2021 · Fabrizio Stocchi, Joaquim Ferreira, et al. · Journal of the Neurological Sciences · 1
The oasis (opicapone in sleep disorder) study in Parkinson's disease: Design and rationale of an open-label, single-arm, pilot trial
2021 · Raquel Costa, Claudia Trenkwalder, et al. · Journal of the Neurological Sciences · 1
Real-World Use of Opicapone in Management of Patients with Parkinson’s Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study
2026 · Lydia López-Manzanares, María Cerdán Sánchez, et al. · Brain Sciences
Su1531: SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS
2022 · Fernando Magro, Diogo Magalhães, et al. · Gastroenterology
Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson's disease patients with motor fluctuations
2021 · Peter Lewitt, Fabrizio Stocchi, et al. · Journal of the Neurological Sciences
PDF
Influence of levodopa daily dose on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
2021 · Camille Carroll, Andrew Lees, et al. · Journal of the Neurological Sciences
Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations
2021 · Angelo Antonini, Georg Ebersbach, et al. · Journal of the Neurological Sciences
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: Findings from the OPTIPARK study
2021 · Heinz Reichmann, Andrew Lees, et al. · Journal of the Neurological Sciences
The ocean (opicapone effect on motor fluctuations and associated pain) study in Parkinson's disease: Design and rationale of a randomized double-blind placebo-controlled trial
2021 · K. Ray Chaudhuri, Per Odin, et al. · Journal of the Neurological Sciences
Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations
2021 · Georg Ebersbach, Werner Poewe, et al. · Journal of the Neurological Sciences
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
2021 · Biju Mohamed, Andrew Lees, et al. · Journal of the Neurological Sciences
Works count: 43
Citation count: 310
H-index: 9
I10-index: 9
Year
Topic
Type